With "solid, convincing evidence that the speculations will actually be realized" in hand, Kite Pharma Inc.'s chief medical officer (CMO), David Chang, told BioWorld Today that the company – just as it hit the primary endpoint in the pivotal trial – will meet the targeted filing of the BLA for its lead chimeric antigen receptor (CAR) T-cell candidate, axicabtagene ciloleucel.